Ebalzotan (NAE-086) is a selective 5-HT1A receptor agonist.[1][2] It was under development as an antidepressant and anxiolytic agent but produced undesirable side effects in phase I clinical trials and was subsequently discontinued.[1][2]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H30N2O2 |
Molar mass | 318.461 g·mol−1 |
3D model (JSmol) | |
|
See also
editReferences
edit- ^ a b Braish T, Gadamasetti KG (2008). Process chemistry in the pharmaceutical industry, volume 2 challenges in an ever changing climate. Boca Raton: CRC Press. ISBN 978-0-8493-9051-7.
- ^ a b Weaver DF, Nogrady T, Nogrady T (2005). Medicinal chemistry a molecular and biochemical approach. Oxford [Oxfordshire]: Oxford University Press. ISBN 0-19-510455-2.